How to select IgG subclasses in developing anti-tumor therapeutic antibodies

Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances

(2020) Hanne Lind et al.   Journal for ImmunoTherapy of Cancer

DuoBody-CD3xCD20 induces potent T-cell-mediated killing of malignant B cells in preclinical models and provides opportunities for subcutaneous dosing

(2020) Patrick J. Engelberts et al.   EBioMedicine

Approaches to treat immune hot, altered and cold tumours with combination immunotherapies

(2019) Jérôme Galon et al.   NATURE REVIEWS DRUG DISCOVERY

Clinical trial update on bispecific antibodies, antibody-drug conjugates, and antibody-containing regimens for acute lymphoblastic leukemia

(2019) Delong Liu et al.   Journal of Hematology & Oncology

Targeting Tumor Microenvironment for Cancer Therapy

(2019) Catarina Roma-Rodrigues et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Bispecific CD3-HAC carried by E1A-engineered mesenchymal stromal cells against metastatic breast cancer by blocking PD-L1 and activating T cells

(2019) Yuanyuan Yang et al.   Journal of Hematology & Oncology

Optimization of 4-1BB antibody for cancer immunotherapy by balancing agonistic strength with FcγR affinity

(2019) Xinyue Qi et al.   Nature Communications

Bispecific antibodies: a mechanistic review of the pipeline

(2019) Aran F. Labrijn et al.   NATURE REVIEWS DRUG DISCOVERY

Human immunoglobulin G hinge regulates agonistic anti-CD40 immunostimulatory and antitumour activities through biophysical flexibility

(2019) Xiaobo Liu et al.   Nature Communications

Uncoupling therapeutic from immunotherapy-related adverse effects for safer and effective anti-CTLA-4 antibodies in CTLA4 humanized mice

(2018) Xuexiang Du et al.   CELL RESEARCH

A reappraisal of CTLA-4 checkpoint blockade in cancer immunotherapy

(2018) Xuexiang Du et al.   CELL RESEARCH

PD-1 Blockade with Cemiplimab in Advanced Cutaneous Squamous-Cell Carcinoma

(2018) Michael R. Migden et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tremelimumab combined with durvalumab in patients with mesothelioma (NIBIT-MESO-1): an open-label, non-randomised, phase 2 study

(2018) Luana Calabrò et al.   Lancet Respiratory Medicine

Avelumab, an IgG1 anti-PD-L1 Immune Checkpoint Inhibitor, Triggers NK Cell-Mediated Cytotoxicity and Cytokine Production Against Triple Negative Breast Cancer Cells

(2018) Estefanía Paula Juliá et al.   Frontiers in Immunology

Fibrinogen-like Protein 1 Is a Major Immune Inhibitory Ligand of LAG-3

(2018) Jun Wang et al.   CELL

Structure of the 4-1BB/4-1BBL complex and distinct binding and functional properties of utomilumab and urelumab

(2018) S. Michael Chin et al.   Nature Communications

Mechanisms of NK Cell Activation and Clinical Activity of the Therapeutic SLAMF7 Antibody, Elotuzumab in Multiple Myeloma

(2018) Kerry S. Campbell et al.   Frontiers in Immunology

Tremelimumab as second-line or third-line treatment in relapsed malignant mesothelioma (DETERMINE): a multicentre, international, randomised, double-blind, placebo-controlled phase 2b trial

(2017) Michele Maio et al.   LANCET ONCOLOGY

Inhibition of Megakaryocyte Differentiation by Antibody–Drug Conjugates (ADCs) is Mediated by Macropinocytosis: Implications for ADC-induced Thrombocytopenia

(2017) Hui Zhao et al.   MOLECULAR CANCER THERAPEUTICS

PD-1 and PD-L1 Checkpoint Signaling Inhibition for Cancer Immunotherapy: Mechanism, Combinations, and Clinical Outcome

(2017) Hashem O. Alsaab et al.   Frontiers in Pharmacology

Phase I study of BMS-663513, a fully human anti-CD137 agonist monoclonal antibody, in patients (pts) with advanced cancer (CA)

(2017) M. Sznol et al.   JOURNAL OF CLINICAL ONCOLOGY

Molecular mechanism of PD-1/PD-L1 blockade via anti-PD-L1 antibodies atezolizumab and durvalumab

(2017) Hyun Tae Lee et al.   Scientific Reports

Therapeutic Activity of Agonistic, Human Anti-CD40 Monoclonal Antibodies Requires Selective FcγR Engagement

(2016) Rony Dahan et al.   CANCER CELL

Results from an Integrated Safety Analysis of Urelumab, an Agonist Anti-CD137 Monoclonal Antibody

(2016) Neil H. Segal et al.   CLINICAL CANCER RESEARCH

A novel BCMA/CD3 bispecific T-cell engager for the treatment of multiple myeloma induces selective lysis in vitro and in vivo

(2016) S Hipp et al.   LEUKEMIA

Antibody-drug conjugates as novel anti-cancer chemotherapeutics

(2015) C. Peters et al.   BIOSCIENCE REPORTS

IL10 and PD-1 Cooperate to Limit the Activity of Tumor-Specific CD8+ T Cells

(2015) Z. Sun et al.   CANCER RESEARCH

Macrophages are critical effectors of antibody therapies for cancer

(2015) Kipp Weiskopf et al.   mAbs

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

(2015) Dongjun Peng et al.   NATURE

Fc-Receptor Interactions Regulate Both Cytotoxic and Immunomodulatory Therapeutic Antibody Effector Functions

(2015) D. J. DiLillo et al.   Cancer Immunology Research

Targeting the PD-1 pathway: a promising future for the treatment of melanoma

(2014) Andrew Mamalis et al.   ARCHIVES OF DERMATOLOGICAL RESEARCH

Potential Mechanisms for Thrombocytopenia Development with Trastuzumab Emtansine (T-DM1)

(2014) H. Uppal et al.   CLINICAL CANCER RESEARCH

Nivolumab for the treatment of cancer

(2014) Anasuya Gunturi et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Production of bispecific antibodies in “knobs-into-holes” using a cell-free expression system

(2014) Yiren Xu et al.   mAbs

Mechanism of Action of Immunotherapy

(2014) Mary L. Disis   SEMINARS IN ONCOLOGY

IgG Subclasses and Allotypes: From Structure to Effector Functions

(2014) Gestur Vidarsson et al.   Frontiers in Immunology

The role of Fc gamma receptors in the activity of immunomodulatory antibodies for cancer

(2014) Ross Stewart et al.   Journal for ImmunoTherapy of Cancer

Engineered antibody Fc variant with selectively enhanced Fc RIIb binding over both Fc RIIaR131 and Fc RIIaH131

(2013) F. Mimoto et al.   PROTEIN ENGINEERING DESIGN & SELECTION

Properties of mouse and human IgG receptors and their contribution to disease models

(2012) P. Bruhns   BLOOD

Targeting of 4-1BB by monoclonal antibody PF-05082566 enhances T-cell function and promotes anti-tumor activity

(2012) Timothy S. Fisher et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Panitumumab (Vectibix): Fig 1.

(2011) J.J. Gemmete et al.   AMERICAN JOURNAL OF NEURORADIOLOGY

An Fcγ Receptor-Dependent Mechanism Drives Antibody-Mediated Target-Receptor Signaling in Cancer Cells

(2011) Nicholas S. Wilson et al.   CANCER CELL

Mechanism of Action of Type II, Glycoengineered, Anti-CD20 Monoclonal Antibody GA101 in B-Chronic Lymphocytic Leukemia Whole Blood Assays in Comparison with Rituximab and Alemtuzumab

(2011) L. Bologna et al.   JOURNAL OF IMMUNOLOGY

Interaction with Fc RIIB Is Critical for the Agonistic Activity of Anti-CD40 Monoclonal Antibody

(2011) A. L. White et al.   JOURNAL OF IMMUNOLOGY

Inhibitory Fc  Receptor Engagement Drives Adjuvant and Anti-Tumor Activities of Agonistic CD40 Antibodies

(2011) F. Li et al.   SCIENCE

Anti-Cancer Actions of Denosumab

(2011) Jameel Iqbal et al.   Current Osteoporosis Reports

Defucosylated Humanized Anti-CCR4 Monoclonal Antibody KW-0761 as a Novel Immunotherapeutic Agent for Adult T-cell Leukemia/Lymphoma

(2010) T. Ishii et al.   CLINICAL CANCER RESEARCH

Daratumumab, a Novel Therapeutic Human CD38 Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors

(2010) M. de Weers et al.   JOURNAL OF IMMUNOLOGY

Suppression of HER2/HER3-Mediated Growth of Breast Cancer Cells with Combinations of GDC-0941 PI3K Inhibitor, Trastuzumab, and Pertuzumab

(2009) E. Yao et al.   CLINICAL CANCER RESEARCH

Specificity and affinity of human Fc  receptors and their polymorphic variants for human IgG subclasses

(2008) P. Bruhns et al.   BLOOD

Potent In vitro and In vivo Activity of an Fc-Engineered Anti-CD19 Monoclonal Antibody against Lymphoma and Leukemia

(2008) H. M. Horton et al.   CANCER RESEARCH